版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
LohmannAnimalHealthInternationalGainesville,Georgia,USA
Education73-84’BSCal.PolyPomonaMSPoultrySc,AuburnDVM,U.C.DavisBoardcertified92’KenTakeshitaFosterFarms,CAMgr.HealthServices85-90’ArborAcres,CTDir.PoultryHealth,91-95’HealthofUSAPed.,GGP,GPTechnicalSupportUSAVinelandLabsDirectorTech.Service;95-01’Worldwide
KenTakeshitaHomeofficeVacaville,CAbetweenSac/SFMgr.TechnicalServicesWorldwidesupportConcentratedeffortinAmerica’sLohmannAnimalHealthInternationalLAHIformedinOctober2000MergerofVineland-MBL-LohmannHeadquarters=GainesvilleGALohmannAnimalHealthInternationalEffectiveMay1,2001TechnicalSupportTeamDr.KenTakeshita(USA)Dr.EricLovell(USA)[Consultant]Dr.DavidShapiro(USA)[Consultant]Dr.GregCutler(USA)[Consultant]Dr.CharlesHofacre(USA)[Consultant]Open(USA)Open(LatinAmerica)Dr.HeikeScharr(Germany)Dr.vanDijk(Germany)Dr.CherYew(Singapore)Dr.BeatrizCardoso(Brazil)Dr.KarenBurns(USA),1/1/02Internationaltrips~same;4/yrwhereverneededworldwideLessintensedomestictravelMorefocusoncustomerfollowuppresentations/techbulletinstrialsandotherprojects
InactivatedIBDVaccinesBursalTissueOrigin(BTO)ChickEmbryoOriginCells(CEO)TissueCultureOrigin(TCO)IBDvirusbursaTC(TissueCulture)CEO(ChickEmbryoOrigin)BTO/BD(BursalTissueOrigin)/(BursalDerived)-ChickenEmbryoFibroblast(CEF)-PerpetualcelllinesSignificantvirusadaptationrequired-Infected,wholechickembryosharvestedSomevirusadaptationrequired-SPFchickensinfectedbursasharvestedVirusadaptationnotrequiredGrowingtheIBDvirusBursalTissueOrigin(BTO)orBursalDerived(BD)BTOvaccinesstartedinUK
Early1970’sOriginatedbygroupofUKveterinariansWerenothappywithliveIBDvaccinesaloneProbablychoseBTObecause:EasytogrowGrewtohightiterUKgovernmentrequiredstrictpotencytestsChallengeofchicksfromvaccinatedparentsTheirworkshowedverystrongprotectioninchicksfromvaccinatedparents(to4weeks)VaccineworkwasledbyDr.BoxandproducedbyGlaxoBTOshowedasbettervaccineLongerdurationofimmunitywhencomparedtoTCOandCEOvaccinesInUSA,betterabletoprotectagainstvariantIBDstrainsFlock’sVaccinatedwithBursalDerivedIBD~BetterTitersFlock’sVaccinatedwithBursalDerivedIBD~BetterProtectionBTOshowedasbettervaccineProduction:BecauseNOvirusadaptationisrequired,finaloutput“matches”seeds/”matches”challengeViralgrowthVeryhightitersbecausevirusis“home”PotentiallyotherimmunefactorsproducedSocalled“bursin”IncompleteviralparticlesViruscontentwhichis“hidden”fromnormalassaybursaTC(TissueCulture)CEO(ChickEmbryoOrigin)BTO/BD(BursalTissueOrigin)/(BursalDerived)AdaptationofIBDvirusFieldVirusSignificantvirusadaptationrequiredSomevirusadaptationrequiredNovirusadaptationrequiredBTObecamewidelyusedFirstusedinbreedersasonlyIBDvaccineand/oraspartofprogramwithliveprogenyvaccination1stBTOvaccineswere>2xcostofTCorCEOvaccinesAstimemovedfrom1970’sto1980’sUK&EuropebegantodeclineusageRegulatoryissuesFearofCAVinthevaccinesAnimalwelfare(usingchickenstomakevaccine)InterferencewithlivevaccinesUSAmovedsolidlytoBTOIBDvaccinesUsedaloneand/orwithliveprogenyvaccinationExcellentcoverageofvariantstrainsVaccinecompaniesclaiming“100%BTO”MBL?Vineland
?BursalTissueOrigin(BTO)VinelandKilled4way“new”
1823~novariantIBD~reducecostequalorbettertiters/protection~sameNDV,IBV&Reoprotection“New”LAHI-VinelandKilled4way“1823”BursalDerivedHowdoes“new”1823comparewithotherkilled4wayvaccinesforIBD?*ProVacACLisproducedinacontinuous,aviancellline–tumortransformedquailcellline.**OnlyMBLBTO2andMerialcontain100%BTOIBDantigen.IBDtitercomparisonof
“new”1823*vsother4ways*Prelicensingserial**Birdsprimedwithlivevaccination.Titersmeasured4weekspostvaccinationBursalDerived~bettertitersBursalDerived~BetterProtection…evenwithsmalldoseQuickQuestions…....orontoVi-BursaCEVi-BursaCEVi-BursaCEa“classic”IBDvirusintermediate<->intermediate+invasiveness“non”cloned~broadspectrumprobagatedinChickEmbryo~broadspectrumgoodsafetyingoodprotectioninbroilersandlayersgoodprimerforkilledvaccinationVi-BursaCEisa“Classic”IBDvirusViBursaGclassicIBDintermediate=D78tissuecultureViBursaCEclassicIBD
intermed.=BursineIIchickembryoViBursaLclassic/variantIBDisamildwon’theatupIBDvirusTC(TissueCulture)CEO(ChickEmbryoOrigin)BursineIIVi-BursaCED78Vi-BursaGVi-BursaCEisproducedinCEOVi-BursaCE….multipliedinlymphoidtissuex1Vi-BursaCEx2a2a178Clone“Non”-clonedclonedD78“Non”-clonedVi-BursaLVi-BursaCEis“non”cloned“non”clonedVi-BursaCE….doesn’tloseit’santigenicdiversity78787878a2a1a1a2x1x1x2x278a1x2Vi-BursaCE….issafeVi-BursaCE…goodprotectioninSPFbirdsVi-BursaCE…. GoodprotectioninbroilersVi-BursaCE…. GoodprimingofkilledVi-BursaCE….goodfieldresultsRecentDevelopments
Vi-BursaCEOriginalVi-BursaCEOriginalVi-BursaCE~lessinvasivethanintendedRecentworkonVi-BursaCERe-workedVi-BursaCE~moreinvasivethanoldNewVi-BursaCENewVi-BursaCE~intermediate<->intermediate+Summary;
Vi-BursaCEa“classic”IBDvirus“non”cloned~broadspectrumprobagatedinChickEmbryo~broadspectrumintermediate<->intermediate+invasivenessgoodsafetyingoodprotectioninbroilersandlayersgoodprimerforkilledvaccinationSummaryRecentdevelopments
Vi-BursaCE“originally”wasVineland’smostinvasiveIBDbutbecame“mild”“current”serialsaremoreinvasivethanoldserialsprobablyslightlylowerin“invasive”nessthanBursine+….analternativetoBursine/Bursine+?ViBursaGclassicIBDintermediate=D78tissuecultureViBursaCEclassicIBD
strongerintermed.
likeBursineIIchickembryoViBursaLMildcausesminimalimunosuppressionToBreakThruLAHI-VinelandLiveIBDVaccinesSummaryRecentdevelopments
Vi-BursaCE“originally”wasVineland’smostinvasiveIBDbutbecame“mild”“current”serialsaremoreinvasivethanoldserialsprobablyslightlylowerin“invasive”nessthanBursine+….analternativetoBursine/Bursine+?Vaccination/challengetrialinprogresstodetermineprotectionagainstvariantvsBursineIIconfirminvasivenessofnewserials“WordofCaution”Thinkcarefullybeforesharing“Recentdevelopments”Vi-BursaCEwithendusercanbeanadvantagewithnewcustomeracustomerwhodidnotseeanadvantageusingthe“old”serialsofVi-BursaCEcanbeadisadvantagewithacurrentuserofVi-BursaCE
…..decideaheadoftimeQuickQuestions…....orontoPD50LAHI-Vineland’sNDVPD50PD50PD50orViNuChickVac-KspecificallydevelopedforbabychickvaccinationcalledPD50becauseeachdosecontains50protectivedosebychallengetestisa“High”-potencykilledNDV
large#ofprotectioninsmallvolume/dosepotencyby
WeybridgeProtectiveDoseTestPD50“High”potency=0.1mldose50PD50“High”potency10PD500.5mldose“Average”potencyvs.
birdsvaccinatedwithdecreasingpartialdoseP(rotective)D(ose)50(%)isdosewhichprotects50%ofbirdschallengedwith“Hot”NDVvirusPD50WeybridgeProtectiveDoseTest=0.1and0.05ml100%protection0.025ml92%protection0.0125ml70%protection0.00612ml30%protecciónThisisthePD50pointExtrapolating,onePD50unitofthisvaccineis.0.009mlCalculationofPD50perdose;-Ifdoseis0.1ml~potencyofvaccineinPD50units=0.1ml/0.009=11-theabovevaccineundertesthasapotencyof11PD50perdose.ExampleofdeterminingPD50ofavaccinePD500.1mldose>50PD50PD5022-25PD500.5mldose“Average”potencyvs.
“Average”killedNDVusedinlayersis
=22-25xPD50in0.3-0.5ml
“High”potencyLAHI-Vineland’sPD50forchicksis>50xPD50in0.1mlPD50Purpose;preventhighlyvelogenicNDVmortalityMethod;Simultaneouslive&killedNDV@1day
liveNDVtostimulatesshortlived(3-5weeks)“l(fā)ocal”(IgA)respiratorymucosalliningimmunityhighpotencykilledtostimulateslonglasting“systemic”(IgG)immunity(@least7-8weeks)
note;it’sessentialthatkilledNDV=“High”PotencyPD50Goalof“Simultaneous”live&killedNDVisfor;MiddleEast;reducemortality40%to4%Mexico;simultaneouskilled/liveeffectiveB1live+LAHI-Vineland’sPD50@1dayLaSota@7-10days+/-LaSota@18dayinhighchallengePD50FieldExperiencePD50FieldExperience;SerologyNosignificantantibodytiterafterdayoldkilledOnlyhightitersafterchallengehightiter+mortality/clinicalsigns~poorprotectionhightiter+nomortality/clinicalsigns~goodprotectionlowtiters~nochallengePD50FieldExperience;SerologyPD50FieldExperience;SerologyThailand
@least0.1ml@1dayofage…challengedependent500mlbottle=5,000dosagesinjectIMinlegorSQinneckPD50Recommendations&Usagewait6hrsbetweenMarek’s&LAHI-Vineland’sPD50preferably
vaccinateindifferentsitefromMarek’sCautionLAHI-Vineland’sNDVQuestions?PD50Questions/AnswersQ.Whatisdifferencebetween“highpotency”PD50vsaveragekilledNDVvsStandardKilledNewcastlevaccines.A.TheantigenamountcontainedinPD50isconsiderablyhigherthanthatinakilledNDVusedinolderlayers.TheprotectiongiventothechickensisconsiderablysuperiorusingViNuChickVacKPD50.PD50Questions/AnswersQ.WhyaretheredifferentkilledNDVrecommendedforbroilerchickensandanotheronerecommendedforlayers?
A.1)Smallerdose,0.1vs0.5ml,ispreferredforonedayoldbroilersbecauseofsizeofbirds2)Higherpotencyispreferredfordayoldbroilersvslayersbecauseofhigherearlierchallenge….particularlywherevelogenicNDVispresent.PD50Questions/Ans
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 外科用肩繃帶相關(guān)項(xiàng)目建議書(shū)
- 基因組信息分析儀項(xiàng)目評(píng)價(jià)分析報(bào)告
- 含藥物的口腔護(hù)理制劑項(xiàng)目評(píng)價(jià)分析報(bào)告
- 做自己的中醫(yī)
- 寶雞文理學(xué)院《材料力學(xué)性能》2022-2023學(xué)年第一學(xué)期期末試卷
- 數(shù)字打字用鉛字項(xiàng)目評(píng)價(jià)分析報(bào)告
- 無(wú)碳紙相關(guān)項(xiàng)目實(shí)施方案
- 有線電視接收器項(xiàng)目評(píng)價(jià)分析報(bào)告
- 部編版三年級(jí)語(yǔ)文上冊(cè)第六單元《這兒真美》教學(xué)課件
- 印刷版項(xiàng)目可行性實(shí)施報(bào)告
- 2024年新人教版七年級(jí)上冊(cè)數(shù)學(xué)課件 3.1 第3課時(shí) 反比例關(guān)系
- 中華民族現(xiàn)代文明有哪些鮮明特質(zhì)?建設(shè)中華民族現(xiàn)代文明的路徑是什么?參考答案
- 教育家精神引領(lǐng)高校教師成長(zhǎng)的解釋框架、認(rèn)知坐標(biāo)與行動(dòng)路徑
- 高職市場(chǎng)營(yíng)銷專業(yè)《市場(chǎng)調(diào)查與預(yù)測(cè)》說(shuō)課稿
- Unit3 My Weekend Plan(教學(xué)設(shè)計(jì))-2024-2025學(xué)年人教PEP版英語(yǔ)六年級(jí)上冊(cè)
- 流產(chǎn)補(bǔ)償協(xié)議樣書(shū)
- 2024年秋季1530安全教育記錄
- DL-T5704-2014火力發(fā)電廠熱力設(shè)備及管道保溫防腐施工質(zhì)量驗(yàn)收規(guī)程
- 中外政治思想史-形成性測(cè)試四-國(guó)開(kāi)(HB)-參考資料
- 撲克牌搭高塔 課件(16張PPT) 小學(xué)班會(huì)活動(dòng)
- 龍井茶PPT課件.ppt
評(píng)論
0/150
提交評(píng)論